Eosinophilic Esophagitis - Pipeline Review, H1 2016

Published: Apr, 2016 | Pages: 61 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Eosinophilic Esophagitis - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Eosinophilic Esophagitis - Pipeline Review, H1 2016', provides an overview of the Eosinophilic Esophagitis pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Eosinophilic Esophagitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Eosinophilic Esophagitis and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Eosinophilic Esophagitis
- The report reviews pipeline therapeutics for Eosinophilic Esophagitis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Eosinophilic Esophagitis therapeutics and enlists all their major and minor projects
- The report assesses Eosinophilic Esophagitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Eosinophilic Esophagitis

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Eosinophilic Esophagitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Eosinophilic Esophagitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope 
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Content 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Eosinophilic Esophagitis Overview 6
Therapeutics Development 7
Pipeline Products for Eosinophilic Esophagitis - Overview 7
Eosinophilic Esophagitis - Therapeutics under Development by Companies 8
Eosinophilic Esophagitis - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Early Stage Products 11
Eosinophilic Esophagitis - Products under Development by Companies 12
Eosinophilic Esophagitis - Companies Involved in Therapeutics Development 13
Celgene Corporation 13
DBV Technologies S.A. 14
Dr. Falk Pharma GmbH 15
Novartis AG 16
Regeneron Pharmaceuticals, Inc. 17
Shire Plc 18
Eosinophilic Esophagitis - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
Allergen for Milk Allergy - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
budesonide - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
budesonide - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
dectrekumab - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
dupilumab - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
fluticasone propionate - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Qi-406 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
RPC-4046 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Eosinophilic Esophagitis - Recent Pipeline Updates 43
Eosinophilic Esophagitis - Dormant Projects 52
Eosinophilic Esophagitis - Product Development Milestones 53
Featured News & Press Releases 53
Nov 12, 2015: DBV Technologies Announces Enrollment of First Patient in Phase IIA Study in Pediatric Eosinophilic Esophagitis 53
Jul 08, 2015: IND Acceptance from FDA for a proof-of-concept trial using Viaskin Milk in Milk-Induced Eosinophilic Esophagitis in Children 53
Oct 03, 2014: Receptos Announces First Patient Treated With Anti-Interleukin-13 Antibody in Phase 2 Trial for Eosinophilic Esophagitis 54
Sep 25, 2014: Meritage Pharma Announces Positive Results of Oral Budesonide Suspension for Treatment of Eosinophilic Esophagitis in Adolescent and Adult Patients 54
Jul 21, 2014: High-dose fluticasone effective against eosinophilic esophagitis 55
May 13, 2014: DBV Technologies Announces Clinical Trial Agreement to Develop a Treatment for Milk-Induced Eosinophilic Esophagitis in Children 56
Aug 13, 2012: Meritage Initiates Clinical Trial Of Oral Budesonide Suspension For Adolescent And Adult Patients With Eosinophilic Esophagitis 57
May 10, 2011: Meritage Pharma Reports Positive Phase IIb Data For Oral Budesonide Suspension In Pediatric Patients With Eosinophilic Esophagitis 57
May 10, 2011: Meritage Reports Positive Phase IIb Data For Oral Budesonide Suspension In Pediatric Patients With Eosinophilic Esophagitis 58
Appendix 60
Methodology 60
Coverage 60
Secondary Research 60
Primary Research 60
Expert Panel Validation 60
Contact Us 60
Disclaimer 61

List of Tables

Number of Products under Development for Eosinophilic Esophagitis, H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Comparative Analysis by Late Stage Development, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 10
Comparative Analysis by Early Stage Development, H1 2016 11
Products under Development by Companies, H1 2016 12
Eosinophilic Esophagitis - Pipeline by Celgene Corporation, H1 2016 13
Eosinophilic Esophagitis - Pipeline by DBV Technologies S.A., H1 2016 14
Eosinophilic Esophagitis - Pipeline by Dr. Falk Pharma GmbH, H1 2016 15
Eosinophilic Esophagitis - Pipeline by Novartis AG, H1 2016 16
Eosinophilic Esophagitis - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016 17
Eosinophilic Esophagitis - Pipeline by Shire Plc, H1 2016 18
Assessment by Monotherapy Products, H1 2016 19
Number of Products by Stage and Target, H1 2016 21
Number of Products by Stage and Mechanism of Action, H1 2016 23
Number of Products by Stage and Route of Administration, H1 2016 25
Number of Products by Stage and Molecule Type, H1 2016 27
Eosinophilic Esophagitis Therapeutics - Recent Pipeline Updates, H1 2016 43
Eosinophilic Esophagitis - Dormant Projects, H1 2016 52